Additionally, our data provided a panel of 14 genes (CD44, COL9A1, FGF1, FGF2, GDF3, GJA1, GJB1, GJB2, HSPA9, KRT15, BMP2, BMP3, EP300, and KAT8) which were expressed (up or downregulated) in all the assessed subsets of BCSCs which could serve as molecular markers with a potential diagnostic, prognostic and/or predictive value for breast cancer patients. This evidence concerns the gene EP300 and breast carcinoma.